Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription


4 AJR Am J Roentgenol
1 Ann Surg
4 Ann Surg Oncol
5 Br J Cancer
2 Breast Cancer
1 Breast Cancer (Dove Med Press)
5 Breast Cancer Res
14 Breast Cancer Res Treat
1 Breast J
2 Cancer
2 Cancer Chemother Pharmacol
3 Cancer Lett
1 Cancer Res
2 Clin Cancer Res
1 Clin Exp Metastasis
1 Eur J Cancer
2 Eur J Surg Oncol
2 Eur Radiol
1 Exp Cell Res
2 Histopathology
2 Int J Cancer
2 Int J Radiat Oncol Biol Phys
7 J Clin Oncol
2 Lancet Oncol
1 Nature
12 NPJ Breast Cancer
1 Oncogene
1 PLoS One
1 Radiology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. KARIMI Z, Phillips J, Slanetz P, Lotfi P, et al
    Factors Associated with Background Parenchymal Enhancement on Contrast Enhanced Mammography.
    AJR Am J Roentgenol. 2020 Jul 8. doi: 10.2214/AJR.19.22353.
    PubMed         Abstract available

  2. BERG WA, Rafferty EA, Friedewald SM, Hruska CB, et al
    Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2021;216:275-294.
    PubMed         Abstract available

  3. GUPTA D, Mendelson EB, Karst I
    Nipple Discharge: Current Clinical and Imaging Evaluation.
    AJR Am J Roentgenol. 2020 Dec 9:1-10. doi: 10.2214/AJR.19.22025.
    PubMed         Abstract available

  4. TEICHGRAEBER DC, Guirguis MS, Whitman GJ
    Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual 8th Edition and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.
    AJR Am J Roentgenol. 2021 Feb 17. doi: 10.2214/AJR.20.25223.
    PubMed         Abstract available

    Ann Surg

  5. NELSON JA, Dabic S, Mehrara BJ, Cordeiro PG, et al
    Breast Implant-associated Anaplastic Large Cell Lymphoma Incidence: Determining an Accurate Risk.
    Ann Surg. 2020;272:403-409.
    PubMed         Abstract available

    Ann Surg Oncol

  6. MA JC, Zhong XR, Luo T, Liu L, et al
    ASO Author Reflections: Postmastectomy Radiotherapy for Breast Cancer Patients After Neoadjuvant Chemotherapy, by Molecular Subtype.
    Ann Surg Oncol. 2021 Feb 18. pii: 10.1245/s10434-020-09555.

  7. LV M, Li J, Guo H, Wang C, et al
    Impact of Ipsilateral Supraclavicular Lymph Node Dissection (ISLND) for Breast Cancer Patients and a Nomogram for Predicting Ipsilateral Supraclavicular Pathological Complete Response (ispCR).
    Ann Surg Oncol. 2021 Feb 17. pii: 10.1245/s10434-020-09548.
    PubMed         Abstract available

  8. MA JC, Zhong XR, Luo T, Xiang ZZ, et al
    The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype.
    Ann Surg Oncol. 2021 Feb 12. pii: 10.1245/s10434-020-09523.
    PubMed         Abstract available

  9. OBENG-GYASI S, Asad S, Fisher JL, Rahurkar S, et al
    Socioeconomic and Surgical Disparities are Associated with Rapid Relapse in Patients with Triple-Negative Breast Cancer.
    Ann Surg Oncol. 2021 Feb 14. pii: 10.1245/s10434-021-09688.
    PubMed         Abstract available

    Br J Cancer

  10. EVANS DG, Phillips KA, Milne RL, Fruscio R, et al
    Survival from breast cancer in women with a BRCA2 mutation by treatment.
    Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01164.
    PubMed         Abstract available

  11. GIORGI ROSSI P, Lebeau A, Canelo-Aybar C, Saz-Parkinson Z, et al
    Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
    Br J Cancer. 2021 Feb 18. pii: 10.1038/s41416-020-01247.
    PubMed         Abstract available

  12. MCCARTNEY A, Malorni L
    Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
    Br J Cancer. 2020;123:176-177.
    PubMed         Abstract available

  13. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed         Abstract available

  14. BUNDRED N, Foden P, Todd C, Morris J, et al
    Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study.
    Br J Cancer. 2020;123:17-25.
    PubMed         Abstract available

    Breast Cancer

  15. OHARA A, Naoi Y, Shimoda M, Tanei T, et al
    Impact of tumor cellularity on the HER2 amplification assay by OncoScan in breast cancer.
    Breast Cancer. 2021 Feb 16. pii: 10.1007/s12282-021-01226.
    PubMed         Abstract available

  16. PARK S, Jeong J, Han W, Lee YJ, et al
    Is mastectomy with immediate reconstruction safe for patients undergoing neoadjuvant chemotherapy? A nationwide study from Korean Breast Cancer Society.
    Breast Cancer. 2021 Feb 14. pii: 10.1007/s12282-021-01223.
    PubMed         Abstract available

    Breast Cancer (Dove Med Press)

  17. DANIYAL A, Santoso I, Gunawan NHP, Barliana MI, et al
    Genetic Influences in Breast Cancer Drug Resistance.
    Breast Cancer (Dove Med Press). 2021;13:59-85.
    PubMed         Abstract available

    Breast Cancer Res

  18. MOURON S, Manso L, Caleiras E, Rodriguez-Peralto JL, et al
    FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
    Breast Cancer Res. 2021;23:21.
    PubMed         Abstract available

  19. PAL CHOUDHURY P, Brook MN, Hurson AN, Lee A, et al
    Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Breast Cancer Res. 2021;23:22.
    PubMed         Abstract available

  20. STENSTROM J, Hedenfalk I, Hagerling C
    Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Breast Cancer Res. 2021;23:27.
    PubMed         Abstract available

  21. KAMINSKA K, Akrap N, Staaf J, Alves CL, et al
    Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Breast Cancer Res. 2021;23:26.
    PubMed         Abstract available

  22. RAMIN C, Withrow DR, Davis Lynn BC, Gierach GL, et al
    Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Breast Cancer Res. 2021;23:24.
    PubMed         Abstract available

    Breast Cancer Res Treat

  23. GEBREMARIAM A, Assefa M, Addissie A, Worku A, et al
    Delayed initiation of adjuvant chemotherapy among women with breast cancer in Addis Ababa, Ethiopia.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06131.
    PubMed         Abstract available

  24. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, Gal R, et al
    (Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06112.
    PubMed         Abstract available

  25. WANG Y, Singh K, Dizon D, Graves T, et al
    Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2021 Feb 17. pii: 10.1007/s10549-021-06124.
    PubMed         Abstract available

  26. JALLOUK AP, Paravastu S, Weilbaecher K, Aft RL, et al
    Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06100.
    PubMed         Abstract available

  27. WARDLEY A, Cortes J, Provencher L, Miller K, et al
    The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06109.
    PubMed         Abstract available

  28. LIZARRAGA IM, Kahl AR, Jacoby E, Charlton ME, et al
    Impact of age, rurality and distance in predicting contralateral prophylactic mastectomy for breast cancer in a Midwestern state: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 13. pii: 10.1007/s10549-021-06105.
    PubMed         Abstract available

  29. LEONE JP, Leone BA, Tayob N, Hassett MJ, et al
    Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06121.
    PubMed         Abstract available

  30. NGUY S, Wu SP, Oh C, Gerber NK, et al
    Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 15. pii: 10.1007/s10549-021-06115.
    PubMed         Abstract available

  31. CAO S, Zhu Z, Zhou J, Li W, et al
    Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06108.
    PubMed         Abstract available

  32. KIM KH, Choi S, Kim K, Chang J, et al
    Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06140.
    PubMed         Abstract available

  33. ALBINSAAD LS, Kim J, Chung IY, Ko BS, et al
    Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06134.
    PubMed         Abstract available

  34. KIM J, Hong S, Lee JJ, Won YJ, et al
    Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06107.
    PubMed         Abstract available

  35. CHEN QX, Yang YZ, Liang ZZ, Chen JL, et al
    Time-varying effects of FOXA1 on breast cancer prognosis.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06125.
    PubMed         Abstract available

  36. RITTER M, Ling BM, Oberhauser I, Montagna G, et al
    The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery.
    Breast Cancer Res Treat. 2021 Feb 19. pii: 10.1007/s10549-021-06126.
    PubMed         Abstract available

    Breast J

  37. TSENG J, Alban RF, Siegel E, Chung A, et al
    Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
    Breast J. 2021 Feb 14. doi: 10.1111/tbj.14191.
    PubMed         Abstract available


  38. OBENG-GYASI S, Timsina LR, Bhattacharyya O, Fisher CS, et al
    Bankruptcy among insured patients with surgical breast cancer: Who is at risk?
    Cancer. 2021 Feb 19. doi: 10.1002/cncr.33468.
    PubMed         Abstract available

  39. BOWER JE, Ganz PA, Irwin MR, Cole SW, et al
    Do all patients with cancer experience fatigue? a longitudinal study of fatigue trajectories in women with breast cancer.
    Cancer. 2021 Feb 19. doi: 10.1002/cncr.33327.
    PubMed         Abstract available

    Cancer Chemother Pharmacol

  40. JUAREZ M, Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, et al
    Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.
    Cancer Chemother Pharmacol. 2020;85:1153-1163.
    PubMed         Abstract available

  41. LYNCE F, Williams JT, Regan MM, Bunnell CA, et al
    Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
    Cancer Chemother Pharmacol. 2021 Feb 14. pii: 10.1007/s00280-021-04245.
    PubMed         Abstract available

    Cancer Lett

  42. ZHANG Y, Fan Y, Jing X, Zhao L, et al
    OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression.
    Cancer Lett. 2021 Feb 12. pii: S0304-3835(21)00068.
    PubMed         Abstract available

  43. ZENG J, Li G, Xia Y, Wang F, et al
    miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.
    Cancer Lett. 2020;492:185-196.
    PubMed         Abstract available

  44. HUANG M, Zhou Y, Duan D, Yang C, et al
    Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib.
    Cancer Lett. 2021 Feb 16. pii: S0304-3835(21)00074.
    PubMed         Abstract available

    Cancer Res

  45. YU R, Longo J, van Leeuwen JE, Zhang C, et al
    Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching.
    Cancer Res. 2021 Feb 18. pii: 0008-5472.CAN-20-2642.
    PubMed         Abstract available

    Clin Cancer Res

  46. SHARMA P, Abramson VG, O'Dea AP, Nye L, et al
    Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-4879.
    PubMed         Abstract available

  47. SINN BV, Loibl S, Hanusch CA, Zahm DM, et al
    Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer.
    Clin Cancer Res. 2021 Feb 16. pii: 1078-0432.CCR-20-3113.
    PubMed         Abstract available

    Clin Exp Metastasis

  48. SONI S, Torvund M, Mandal CC
    Molecular insights into the interplay between adiposity, breast cancer and bone metastasis.
    Clin Exp Metastasis. 2021 Feb 16. pii: 10.1007/s10585-021-10076.
    PubMed         Abstract available

    Eur J Cancer

  49. STRADELLA A, Del Valle J, Rofes P, Vargas-Parra G, et al
    ERCC3, a new ovarian cancer susceptibility gene?
    Eur J Cancer. 2020;141:1-8.
    PubMed         Abstract available

    Eur J Surg Oncol

  50. RAUTALIN M, Jahkola T, Roine RP
    Surgery and health-related quality of life - A prospective follow up study on breast cancer patients in Finland.
    Eur J Surg Oncol. 2021 Feb 9. pii: S0748-7983(21)00089.
    PubMed         Abstract available

  51. CULLINANE C, Shrestha A, Al Maksoud A, Rothwell J, et al
    Optimal timing of surgery following breast cancer neoadjuvant chemotherapy: A systematic review and meta-analysis.
    Eur J Surg Oncol. 2021 Feb 9. pii: S0748-7983(21)00055.
    PubMed         Abstract available

    Eur Radiol

  52. KIM G, Mikhael PG, Oseni TO, Bahl M, et al
    Ductal carcinoma in situ on digital mammography versus digital breast tomosynthesis: rates and predictors of pathologic upgrade.
    Eur Radiol. 2020;30:6089-6098.
    PubMed         Abstract available

  53. WANG J, Chien N, Lee HT
    Clip migration after stereotactic vacuum-assisted breast biopsy with the patient in the decubitus position.
    Eur Radiol. 2020;30:6080-6088.
    PubMed         Abstract available

    Exp Cell Res

  54. NAIR MG, Somashekaraiah VM, Ramamurthy V, Prabhu JS, et al
    miRNAs: Critical mediators of breast cancer metastatic programming.
    Exp Cell Res. 2021 Feb 16:112518. doi: 10.1016/j.yexcr.2021.112518.
    PubMed         Abstract available


  55. ALATAKI A, Zabaglo L, Tovey H, Dodson A, et al
    A simple digital image analysis for automated Ki67 assessment in primary breast cancer.
    Histopathology. 2021 Feb 15. doi: 10.1111/his.14355.
    PubMed         Abstract available

  56. ELSHARAWY KA, Gerds TA, Rakha EA, Dalton LW, et al
    Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision.
    Histopathology. 2021 Feb 15. doi: 10.1111/his.14354.
    PubMed         Abstract available

    Int J Cancer

  57. TRAN QH, Than VT, Luu PL, Clarke D, et al
    A Novel Signature Predicts Recurrence Risk and Therapeutic Response in Breast Cancer Patients.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33512.
    PubMed         Abstract available

  58. KIM N, Chang JS, Shah C, Shin H, et al
    Hypofractionated volumetric-modulated arc therapy for breast cancer: A propensity-score-weighted comparison of radiation-related toxicity.
    Int J Cancer. 2021 Feb 18. doi: 10.1002/ijc.33525.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  59. LALANI N, Jimenez RB, Yeap B
    Understanding Propensity Score Analyses.
    Int J Radiat Oncol Biol Phys. 2020;107:404-407.

  60. POPPE MM, Yehia ZA, Baker C, Goyal S, et al
    5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.
    Int J Radiat Oncol Biol Phys. 2020;107:694-700.
    PubMed         Abstract available

    J Clin Oncol

  61. MAMOUNAS EP, Mitchell MP, Woodward WA
    Molecular Predictive and Prognostic Markers in Locoregional Management.
    J Clin Oncol. 2020;38:2310-2320.

  62. WHITE J, Thompson A, Whelan T
    Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.
    J Clin Oncol. 2020;38:2254-2262.

  63. HWANG ES, Solin L
    De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.
    J Clin Oncol. 2020;38:2230-2239.

  64. MORROW M, Khan AJ
    Locoregional Management After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2020;38:2281-2289.

  65. SHUMWAY DA, Momoh AO, Sabel MS, Jagsi R, et al
    Integration of Breast Reconstruction and Postmastectomy Radiotherapy.
    J Clin Oncol. 2020;38:2329-2340.

  66. TING FIL
    The Road Less Traveled: Serving the Underserved.
    J Clin Oncol. 2020;38:2597-2598.

    Reply to R.T. Chlebowski et al.
    J Clin Oncol. 2020;38:3072-3073.


    Donning and Doffing.
    JAMA. 2021;325:536.

    Lancet Oncol

  69. XU B, Yan M, Ma F, Hu X, et al
    Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2021 Feb 11. pii: S1470-2045(20)30702.
    PubMed         Abstract available

    More women dismissing breast reconstruction after mastectomy.
    Lancet Oncol. 2021;22:e43.


  71. LI S, Liu M, Do MH, Chou C, et al
    Cancer immunotherapy via targeted TGF-beta signalling blockade in TH cells.
    Nature. 2020;587:121-125.
    PubMed         Abstract available

    NPJ Breast Cancer

  72. KANTOR O, Wong S, Weiss A, Metzger O, et al
    Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.
    NPJ Breast Cancer. 2020;6:35.
    PubMed         Abstract available

  73. KUEMMEL S, Harrach H, Schmutzler RK, Kostara A, et al
    Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
    NPJ Breast Cancer. 2020;6:31.
    PubMed         Abstract available

  74. PATEL JM, Goss A, Garber JE, Torous V, et al
    Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    NPJ Breast Cancer. 2020;6:19.
    PubMed         Abstract available

  75. LAMBERTINI M, Ceppi M, Hamy AS, Caron O, et al
    Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.
    NPJ Breast Cancer. 2021;7:16.
    PubMed         Abstract available

  76. ZENG Z, Vo A, Li X, Shidfar A, et al
    Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer.
    NPJ Breast Cancer. 2020;6:24.
    PubMed         Abstract available

  77. GOODWIN PJ, Segal RJ, Vallis M, Ligibel JA, et al
    The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.
    NPJ Breast Cancer. 2020;6:6.
    PubMed         Abstract available

  78. DOWSETT M, Ellis MJ, Dixon JM, Gluz O, et al
    Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
    NPJ Breast Cancer. 2020;6:21.
    PubMed         Abstract available

  79. SEHL ME, Carroll JE, Horvath S, Bower JE, et al
    The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients.
    NPJ Breast Cancer. 2020;6:23.
    PubMed         Abstract available

  80. WOLFF JL, Aufill J, Echavarria D, Blackford AL, et al
    A randomized intervention involving family to improve communication in breast cancer care.
    NPJ Breast Cancer. 2021;7:14.
    PubMed         Abstract available

  81. ROBERTSON JFR, Di Leo A, Johnston S, Chia S, et al
    Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.
    NPJ Breast Cancer. 2021;7:11.
    PubMed         Abstract available

  82. BERGHOLTZ H, Lien TG, Swanson DM, Frigessi A, et al
    Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.
    NPJ Breast Cancer. 2020;6:26.
    PubMed         Abstract available

  83. GRIGUOLO G, Dieci MV, Pare L, Miglietta F, et al
    Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
    NPJ Breast Cancer. 2021;7:12.
    PubMed         Abstract available


  84. BUTTI R, Nimma R, Kundu G, Bulbule A, et al
    Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression.
    Oncogene. 2021 Feb 18. pii: 10.1038/s41388-021-01663.
    PubMed         Abstract available

    PLoS One

  85. SANDOVAL RL, Leite ACR, Barbalho DM, Assad DX, et al
    Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    PLoS One. 2021;16:e0247363.
    PubMed         Abstract available


  86. ZARIC O, Farr A, Minarikova L, Lachner S, et al
    Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study.
    Radiology. 2021 Feb 16:201600. doi: 10.1148/radiol.2021201600.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.